There is a higher probability of being a long-term survivor among patients with advanced lung cancer and mutations in other treatable molecular targets, excluding the ones mentioned earlier (ROS1, ALK, EGFR, PD-L1)b. This evidence concerns the gene ROS1 and lung carcinoma.